drugset
drugset / Trial / NCT02211924

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 44847 Administered to Healthy Male Subjects

NCT02211924 ↗

Phase 1 Completed 48 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 44847 in Japanese healthy volunteers

Timeline

Start
2007-08
Primary completion
2007-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 44847 Unknown 50 mg Oral
Subject BI 44847 Unknown 800 mg Oral

Indications

No indication recorded.